Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements study identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://stepheny568sqt3.wikimidpoint.com/user